Physician profile
Akash Patnaik
NPI 1750360962
$40,430.24
in general payments reported to CMS, 2019-2025
15 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,131 · 2021: $50.00 · 2022: $1,784 · 2023: $2,565 · 2024: $2,836 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $2,784 · Travel and Lodging: $1,407 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,355.00 |
| Food and Beverage | $2,783.64 |
| Travel and Lodging | $1,406.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19,476.97 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $9,126.06 | 2024-2025 | Truqap |
| Exelixis INC. | $3,796.92 | 2020-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $2,630.77 | 2023-2025 | |
| Tolmar, INC. | $2,250.00 | 2025 | |
| Janssen Global Services, LLC | $1,855.97 | 2024 | |
| Genzyme Corporation | $429.95 | 2019 | |
| Pfizer INC. | $285.00 | 2024-2025 | |
| Bristol Myers Squibb Company | $221.13 | 2020 | |
| Janssen Biotech, INC. | $116.06 | 2020 | |
| Gilead Sciences, INC. | $100.33 | 2024 | |
| Dendreon Pharmaceuticals LLC | $65.66 | 2022 | |
| Clovis Oncology, INC. | $50.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.42 | 2023 | Lifevest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akash Patnaik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.